Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma.
Atrash S, Ali SA, Usmani SZ. Atrash S, et al. Among authors: usmani sz. Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):21-34. doi: 10.1016/j.clml.2020.08.027. Epub 2020 Sep 18. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33046423 Review.
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Holstein SA, Bahlis N, Bergsagel PL, Bhutani M, Bolli N, Brownstein C, Demolis P, Foureau D, Gay F, Ghobrial IM, Gormley N, Hillengass J, Kaiser M, Maus MV, Melenhorst JJ, Merz M, Dwyer MO, Paiva B, Pasquini MC, Shah N, Wong SW, Usmani SZ, McCarthy PL. Holstein SA, et al. Among authors: usmani sz. Transplant Cell Ther. 2021 Oct;27(10):807-816. doi: 10.1016/j.jtct.2021.05.027. Epub 2021 Jun 6. Transplant Cell Ther. 2021. PMID: 34107340 Free PMC article. Review.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Berdeja JG, et al. Among authors: usmani sz. Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24. Lancet. 2021. PMID: 34175021 Clinical Trial.
Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A. Sidana S, et al. Transplant Cell Ther. 2022 Feb;28(2):83.e1-83.e9. doi: 10.1016/j.jtct.2021.10.022. Epub 2021 Nov 12. Transplant Cell Ther. 2022. PMID: 34781066 Free PMC article.
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S, Usmani SZ, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schecter JM, Kumar S, Hari P. Costa LJ, et al. Among authors: usmani sz. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):326-335. doi: 10.1016/j.clml.2021.10.013. Epub 2021 Oct 30. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34840088
266 results